Prosecution Insights
Prosecution Insights
5 pending office actions • 3 clients • 5 examiners • 5 art units • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (20%) |
| §103 only | 2 (40%) |
| Double-patenting only | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HELLMAN, KRISTINA M | 1 | 65.7% | +54.8% |
| EIX, EMILY FAY | 1 | 53.6% | +68.4% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.0% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.2% |
| REYNOLDS, FRED H | 1 | 33.1% | +39.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18785340 | Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia | HELLMAN, KRISTINA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17634034 | Hydrophobic Peptide Salts for Extended Release Compositions | REYNOLDS, FRED H | 334d overdue |
| 17829620 | Lysosomal Targeting Peptides and Uses Thereof | ALLEN, MARIANNE P | 38d overdue |
| 18148888 | COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY, MOYAMOYA DISEASE, MOYAMOYA SYNDROME AND INTIMAL PROLIFERATION | SZPERKA, MICHAEL EDWARD | 14d |
| 18785340 | Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia | HELLMAN, KRISTINA M | — |
| 18529611 | METHODS FOR TREATING LYSOSOMAL STORAGE DISEASES | EIX, EMILY FAY | — |
| Client (Assignee) | Pending OAs |
|---|---|
| BioMarin Pharmaceutical | 3 |
| Rutgers University | 1 |
| University of Münster | 1 |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1653 | 1 |
| 1641 | 1 |
| 1647 | 1 |
| 1658 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18785340 | Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia | BIOMARIN PHARMACEUTICAL INC. | HELLMAN, KRISTINA M | 1654 | §101 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18529611 | METHODS FOR TREATING LYSOSOMAL STORAGE DISEASES | Rutgers, The State University Of New Jersey | EIX, EMILY FAY | 1653 | DP | Non-Final OA | — | Pending | Dec 05, 2023 |
| 18148888 | COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY, MOYAMOYA DISEASE, MOYAMOYA SYNDROME AND INTIMAL PROLIFERATION | Westfälische Wilhelms-Universität Münster | SZPERKA, MICHAEL EDWARD | 1641 | §103 | Non-Final OA | 14d | Pending | Dec 30, 2022 |
| 17829620 | Lysosomal Targeting Peptides and Uses Thereof | BIOMARIN PHARMACEUTICAL INC. | ALLEN, MARIANNE P | 1647 | §103 | Non-Final OA | 38d overdue | Pending | Jun 01, 2022 |
| 17634034 | Hydrophobic Peptide Salts for Extended Release Compositions | BIOMARIN PHARMACEUTICAL INC. | REYNOLDS, FRED H | 1658 | Other | Non-Final OA | 334d overdue | Pending | Feb 09, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial